A Phase 3 interventional study of Placebo and Brexpiprazole 1 mg in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Terminated at 2 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 13th largest by enrollment, is one of 7 that started in 2013, is one of 16 in phase 3, and was the 8th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 7 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 129 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
36 studies in Depressive Disorder, Major by H. Lundbeck A/S: none open now, none under way, none of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 36 studies in Depressive Disorder, Major by H. Lundbeck A/S, this one is the 24th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2013, is one of 21 in phase 3, and was the 17th registered.
H. Lundbeck A/S’s Depressive Disorder, Major studies by the year they started, since 2005.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among H. Lundbeck A/S’s 36 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of brexpiprazole as adjunctive treatment in elderly patients with Major Depressive Disorder (MDD)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)
Drug: Placebo
Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week followed by 1 mg/day.
Drug: Brexpiprazole 1 mg
Brexpiprazole adjunct to open-label treatment with a commercially available ADT. Brexpiprazole dosing was 0.5 mg/day in the first 1 week, 1 mg/day in the second week, followed by 3 mg/day.
Drug: Brexpiprazole 3 mg
Once daily, tablets, orally
once daily dose, tablets, orally
once daily dose, tablets, orally
Change From Randomisation in Depressive Symptoms During the Randomised Treatment
Montgomery and Aasberg Depression Rating Scale (MADRS) total score
Time frame: From randomisation to end of treatment (week 20)
Number of Adverse Events
15 patients were enrolled to Period 2; only 3 patients completed due to study termination
Time frame: From randomisation to follow-up (week 24)
Change From Randomisation in Clinical Global Impression During the Randomised Treatment
Clinical Global Impression - Severity of illness (CGI-S) score
Time frame: From randomisation to end of treatment (week 20)
Change From Randomisation in Functionality Assessed by SDS During the Randomised Treatment
Sheehan Disability Scale (SDS) total score
Time frame: From randomisation to end of treatment (week 20)
Change From Randomisation in Social Adaptation During the Randomised Treatment
Social Adaptation Self-evaluation Scale (SASS) total score
Time frame: From randomisation to end of treatment (week 20)
Response During the Randomised Treatment
Based on a pre-specified decrease in MADRS total score
Time frame: From randomisation to end of treatment (week 20)
Sustained Response During the Randomised Treatment
Based on a pre-specified decrease in MADRS total score
Time frame: From randomisation to end of treatment (week 20)
Remission During the Randomised Treatment
Based on a pre-specified MADRS total score
Time frame: From randomisation to end of treatment (week 20)
Sustained Remission During the Randomised Treatment
Based on a pre-specified MADRS total score
Time frame: From randomisation to end of treatment (week 20)
Number of Patients With Risk of Suicidality Assessed Using the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour.
Time frame: From randomisation to end of treatment (week 20)
129 patients were enrolled in the study and 128 patients received open-label treatment with one of six commercially available antidepressant antidepressant treatments (ADT) together with double-blind study treatment. Only 15 patients were randomized to Period 2 before the study was terminated; 47 patients entered Period 3.
| Milestone | Period 1 Placebo and ADT | Period 2 Placebo and ADT | Period 2 Brexpiprazole 1 mg and ADT | Period 2 Brexpiprazole 3 mg and ADT | Period 3 Placebo and ADT |
|---|---|---|---|---|---|
| Started | 129 | 0 | 0 | 0 | 0 |
| Completed | 27 | 0 | 0 | 0 | 0 |
| Not completed | 102 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 9 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Administrative reasons | 76 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal of consent before treatment | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 10 | 0 | 0 | 0 | 0 |
| Milestone | Period 1 Placebo and ADT | Period 2 Placebo and ADT | Period 2 Brexpiprazole 1 mg and ADT | Period 2 Brexpiprazole 3 mg and ADT | Period 3 Placebo and ADT |
|---|---|---|---|---|---|
| Started | 0 | 6 | 3 | 6 | 0 |
| Completed | 0 | 1 | 1 | 1 | 0 |
| Not completed | 0 | 5 | 2 | 5 | 0 |
| Withdrew: Administrative or other reasons | 0 | 5 | 2 | 4 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Milestone | Period 1 Placebo and ADT | Period 2 Placebo and ADT | Period 2 Brexpiprazole 1 mg and ADT | Period 2 Brexpiprazole 3 mg and ADT | Period 3 Placebo and ADT |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 47 |
| Completed | 0 | 0 | 0 | 0 | 24 |
| Not completed | 0 | 0 | 0 | 0 | 23 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Administrative reasons | 0 | 0 | 0 | 0 | 20 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 2 |
15 patients were enrolled to Period 2; only 3 patients completed due to study termination
| Adverse events | Period 2 Placebo and ADT | Period 2 Brexpiprazole 1 mg and ADT | Period 2 Brexpiprazole 3 mg and ADT |
|---|---|---|---|
| Number of Adverse Events | 3 | 5 | 2 |
Montgomery and Aasberg Depression Rating Scale (MADRS) total score
No measurements were reported for this outcome.
Clinical Global Impression - Severity of illness (CGI-S) score
No measurements were reported for this outcome.
Sheehan Disability Scale (SDS) total score
No measurements were reported for this outcome.
Social Adaptation Self-evaluation Scale (SASS) total score
No measurements were reported for this outcome.
Based on a pre-specified decrease in MADRS total score
No measurements were reported for this outcome.
Based on a pre-specified decrease in MADRS total score
No measurements were reported for this outcome.
Based on a pre-specified MADRS total score
No measurements were reported for this outcome.
Based on a pre-specified MADRS total score
No measurements were reported for this outcome.
The Columbia Suicide Severity Rating Scale (eC-SSRS) is a semi-structured interview developed to systematically assess suicidal ideation and behaviour of patients participating in a clinical study. The C-SSRS has 5 questions addressing suicidal ideation, 5 sub-questions assessing the intensity of ideation, and 4 questions addressing suicidal behaviour.
| participants | Period 2 Placebo and ADT | Period 2 Brexpiprazole 1 mg and ADT | Period 2 Brexpiprazole 3 mg and ADT |
|---|---|---|---|
| No suicidal ideation or behaviour | 6 | 3 | 4 |
| Any non-suicidal self-injurious behavior | 0 | 0 | 0 |
| Suicidal Ideation | 0 | 0 | 2 |
| Preparatory action towards imminent suicidal behav | 0 | 0 | 0 |
| Not fatal suicide attempt | 0 | 0 | 0 |
| Completed suicide | 0 | 0 | 0 |
Collected over From randomization to follow-up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 2 Placebo and ADT | — | 0/6 (0%) | 2/6 (33.3%) |
| Period 2 Brexpiprazole 1 mg and ADT | — | 0/3 (0%) | 2/3 (66.7%) |
| Period 2 Brexpiprazole 3 mg and ADT | — | 0/6 (0%) | 2/6 (33.3%) |
| Event | Period 2 Placebo and ADT | Period 2 Brexpiprazole 1 mg and ADT | Period 2 Brexpiprazole 3 mg and ADT |
|---|---|---|---|
| Gait disturbanceGeneral disorders | 0/6 | 1/3 | 0/6 |
| Weight increasedInvestigations | 0/6 | 1/3 | 0/6 |
| DizzinessNervous system disorders | 0/6 | 1/3 | 0/6 |
| TremorNervous system disorders | 0/6 | 1/3 | 0/6 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/6 | 1/3 | 0/6 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/6 | 0/3 | 0/6 |
| Parkinson's diseaseNervous system disorders | 0/6 | 0/3 | 1/6 |
| BruxismPsychiatric disorders | 1/6 | 0/3 | 0/6 |
| InsomniaPsychiatric disorders | 0/6 | 0/3 | 1/6 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/6 | 0/3 | 0/6 |
| Age, Categorical(Participants) | Period 2 Placebo and ADT | Period 2 Brexpiprazole 1 mg and ADT | Period 2 Brexpiprazole 3 mg and ADT | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 6 | 3 | 6 | 15 |
| Sex: Female, Male(Participants) | Period 2 Placebo and ADT | Period 2 Brexpiprazole 1 mg and ADT | Period 2 Brexpiprazole 3 mg and ADT | Total |
|---|---|---|---|---|
| Female | 3 | 2 | 6 | 11 |
| Male | 3 | 1 | 0 | 4 |
The record gives a start of Apr 2013, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole